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Randomized controlled trials of dietary supplements to
slow cognitive decline in older adults with and without Alz-
heimer’s disease or mild cognitive impairment have been
disappointing [1–5] with some notable exceptions [3,6–8].
These well-executed trials have raised important questions
as to how robust epidemiological and preclinical evidence
can meet inconclusive trial results. Two possible explana-
tions include supplementation in the general population, ir-
respective of the individuals’ nutritional status, and the
lack of insight into the potential interactive qualities among
nutrients. Approaches to better understand nutritional status
and nutrient interaction may help advance the field. This
notion has emerged in trials of homocysteine (HCy)-
lowering B vitamins to slow cognitive decline and reduce to-
tal brain atrophy in people with hyperhomocysteinemia and
higher baseline n-3 polyunsaturated fatty acid (PUFA) in cir-
culation [7,9]. These findings are consistent with several
other nutritional interventions in older adults that targeted
those with suboptimum nutritional status in primary [6] or
secondary analyses [10] or determined a posteriori that
baseline nutritional status dictated efficacy [2,3,8].
The literature on food and nutrient interaction is limited
and fragmented across disciplines [9,11–14]. More recent
studies of nutrient biomarker patterns do capture the
interactive properties among nutrients and may explain
significant variance in domain-specific cognitive functions
[15], long-term risk for dementia [16], and more favorable
neuroimaging parameters [15,17]. These US and French
studies across different populations by different groups
implicate n-3 PUFA, HCy-lowering B vitamins, and D as po-
tential nutritional requirements for healthy cognitive aging.
However, more longitudinal studies are needed to establish
thresholds for biomarkers of diet quality in terms of cogni-
tive health. Although each of these nutrients have been or
are currently undergoing trial testing [18] (clinicaltrials.gov:
NCT03613116), their combination may ultimately prove
most beneficial through a variety of interactive mechanisms.
For instance, the n-3 PUFAs have known anti-inflammatory
and synaptogenic properties, and the HCy-lowering B vita-
mins may improve blood-brain barrier integrity [19,20],
one carbon [21,22] and tau metabolism [21], whereas D
may promote neurogenesis by maintaining day-to-day clear-
ance of soluble amyloid-beta (Ab) oligomers from the cen-
tral nervous system (CNS) into the periphery [23–28].
Nutrient biomarkers that include blood-based nutrients,
subsequent metabolites, or metabolic indicators thereof
can allow the objective assessment of diet quality and
nutrient interaction in relation to cognitive decline and de-
mentia risk. In this study, a blood-based nutritional risk in-
dex (NRI) is proposed that captures n-3 PUFA, D, andHCy at baseline in participants of the multidomain Alz-
heimer prevention trial (MAPT). Cutoffs for each biomarker
were prespecified using the existing literature forming an
NRI score of 0–3 for each participant depending on the num-
ber of suboptimum nutrient biomarker concentrations iden-
tified. This way of investigating nutritional risk for cognitive
decline can support or refute a role for nutrient interaction
and nutritional status in conferring risk for cognitive decline.
Given that the MAPT reported null results, we hypothesized
that the NRI explains 3-year cognitive trajectories in these
older adults at risk for dementia.2. Methods
2.1. Study population
The full detailed methods for MAPT are described else-
where [29,30]. The MAPT was a multicenter, randomized,
and placebo-controlled trial with four treatment arms,
including (1) multidomain intervention (MDI) plus placebo,
(2) MDI plus n-3 PUFA, (3) supplementation with n-3 PUFA
without MDI, and (4) placebo-only group followed for more
than 3 years. TheMDI included nutritional counseling, phys-
ical activity, and cognitive training. Individualized preven-
tive outpatient visits also explored possible risk factors for
cognitive decline at baseline, 1 year, and 2 years [31]. Small
group training sessions in six to eight participants for more
than twelve 120-minute sessions lasted the first 2 months
(two sessions a week for the first month and one session a
week the second month). Each session includes 60 minutes
of cognitive training, 45 minutes of physical training, and
15 minutes of nutritional counseling. Starting on the third
month, 60-minute sessions each month throughout the 3-
year intervention period were conducted to reinforce the
key messages of the program and increase compliance. De-
tails on the cognitive and physical training and the nutritional
counseling are described in detail elsewhere [29].
The MAPT was conducted in 13 memory centers across
France and Monaco by experts in the diagnosis and manage-
ment of cognitive impairment and dementia. Community-
dwelling elders aged 70 and older meet at least one of three
criteria placing them at risk for cognitive decline: subjective
memory complaint expressed to their physician, limitation
in one instrumental activity of daily living, or gait speed re-
corded at 0.8 m/s or.5 seconds to walk 4 m. Participants
with a Mini-Mental State Examination score below 24, de-
mentia, difficulty in basic activities of daily living, and those
taking n-3 PUFA supplements were excluded.
Blood draw and banking of biospecimens yielded 729
volunteers with baseline blood samples available for nutrient
biomarker analysis, of which, 712 had complete data to carry
out hypothesis testing. The demographic and clinical
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the MAPT participants missing baseline biospecimens
(n 5 968) were similar in age (mean age, 75.6 vs. 75.1,
P 5 .17 via t test), cognitive composite Z scores (20.028
vs. 20.011, P 5 .14 via t test), and education (no diploma:
23.6% vs. 21.8%; secondary education: 34.3% vs. 33.2%;
high-school diploma: 14.6% vs. 14.8%; and university level:
27.5% vs. 30.2%, P5 .63 via chi-square test). Our study had
a marginally higher prevalence of women (67.4% vs. 62.8%,
P 5 .049 chi-squared test).
2.2. Ethical approval
The trial protocol was approved by the French Ethics
Committee located in Toulouse and authorized by the French
Health Authority. The MAPT/Data Sharing Alzheimer
(DSA) group approved the present study protocol permitting
availability of tissue and existing data to carry out the spe-
cific research aims.
2.3. Neuropsychological assessments
TheMAPT cognitive composite Z scorewas derived from
the following four tests: (1) free and total recall of the free
and cued selective reminding test [32]; (2) 10 Mini-Mental
State Examination orientation items; (3) the digit symbol
substitution test score from the Wechsler Adult Intelligence
Scale–Revised [33]; and (4) the verbal fluency category test
(i.e., 2 minutes of category fluency in animals) [34]. Baseline
mean and standard deviation for each test were used to
calculate baseline and longitudinal cognitive Z scores [30].
2.4. Nutrient biomarker assays2.4.1. Erythrocyte n-3 PUFA
The percentage of eicosapentaenoic acid (EPA, 20:5n-3)
and docosahexaenoic acid (DHA, 22:6n-3) was quantified
using gas chromatography coupled with a flame ionization
detector (GC-FID) and denoted as n-3 PUFA. Erythrocytes
are separated from plasma by centrifugation and washed
three times before lipid extraction by the Folch method
including a mixture of hexane and isopropanol after acidifi-
cation. Margaric acid is added as an internal standard
(Sigma). Total lipid extracts were saponified and methyl-
ated. Fatty acid methyl esters were extracted with pentane
and analyzed by GC using an Agilent Technologies 6890N
gas chromatograph with a split injector, a bonded silica
capillary column (BPX 70, 60 m ! 0.25 mm; 0.25 mm of
film thickness) and an FID. Helium was used as a carrier
gas, and the column temperature program started at 150C,
increased by 1.3C/min to 220C and held at 220C for
10 minutes [35]. Identification of fatty acid methyl esters
was based on retention times obtained from fatty acid stan-
dards. The area under the curvewas determined using Chem-
Station software (Agilent). EPA and DHA concentrations
are calculated using internal standards and expressed asmicrograms/grams of erythrocytes. Fatty acid methyl ester
is quantifiable after transmethylation using a GC 2100 Gas
Chromatograph equipped with a silica capillary column
(Shimadzu). Programmed temperature spray injector and
an FID calculated the percentage of EPA and DHA of total
fatty acids identified.
2.4.2. Serum 25-hydroxyvitamin D
An electrochemiluminescence binding assay was used for
the in vitro determination of total D (Cobas 8000; Roche).
This assay used vitamin D-binding protein (VDBP) to cap-
ture and quantify total serum D, which includes 25-
hydroxyvitamin D3 and D2 [36]. The sample is incubated
with a pretreatment reagent for 9 minutes that denatures
the natural VDBP in the sample and releases the bound D.
The sample is then further incubated with a recombinant
ruthenium-labeled VDBP to form a complex of D and the
ruthenylated VDBP. The addition of a biotinylated D creates
a compound of the ruthenium-labeled VDBP and the bio-
tinylated D. The entire complex becomes bound to the solid
phase by the interaction of biotin and streptavidin-coated
microparticles, which are captured on the surface of the elec-
trode. The unbound substances are removed. Adding voltage
to the electrode induces a chemiluminescent and quantifi-
able emission by a photomultiplier. Results are determined
via an instrument-specific calibration curve generated by a
two-point calibration and master curve provided by the re-
agent barcode yielding units expressed in nanogram/milli-
liter.
2.4.3. Plasma homocysteine
Total plasma HCy was measured using a commercially
available enzymatic cycling assay (Cobas 8000; Roche)
[37]. The concentration of total plasma HCy was measured
in plasma samples against a standard curve. Oxidized HCy
was first reduced and then reacted with S-adenosylmethio-
nine to form methionine and S-adenosyl HCy (SAH) in the
presence of HCy S-methyl transferase. SAH is then assessed
by coupled enzymatic reactions where SAH is hydrolyzed
into adenosine and HCy by SAH hydrolase, and HCy is
cycled back into the HCy conversion reaction that serves
to amplify the detection signal. The formed adenosine is
hydrolyzed into inosine and ammonia. Glutamate dehydro-
genase catalyzes the reaction of ammonia with 2-
oxoglutarate and nicotinamide adenine dinucleotide to
form NAD1. The concentration of HCy is then directly pro-
portional to the amount of nicotinamide adenine dinucleo-
tide converted to NAD1, which is read at an absorbance of
340 nm. This yields units expressed as mmol/L.2.5. Construction of an NRI for cognition using
biomarkers of diet quality
This NRI was conceptualized as an objective and quanti-
tative measure of the nutrition-related risk for age-related
cognitive decline and dementia. Three nutrient biomarkers
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available bioanalytical assays, plausible mechanisms of ac-
tion relevant to the pathogenesis of Alzheimer dementia or
vascular dementia, and modifiable through diet and supple-
mentation. The nutrient biomarkers included the following:
(1) erythrocyte n-3 PUFA [38–41]; (2) serum total D
[42–44,65], and (3) plasma total HCy, a sulfur-containing
amino acid and metabolic indicator of one-carbon meta-
bolism sensitive to B vitamin intake (B6, B9, B12, and
betaine) [21,45].
The NRI indicates the number of nutritional risk
factors for cognitive decline using a relatively simple
and readily available blood test. The operationalized
cutoffs for nutritional risk include the following:
n-3 PUFA (4.82 wt% 5 1) [30,46,47], serum D
(20 ng/mL 5 1) [48,65], and plasma HCy
(14 mmol/L 5 1) [49]. NRI scores range from 0 (optimu-
mor clear of nutritional risk) to 3 (maximum nutritional
risk). Because three nutrient biomarkers were included
there were a total of eight possible nutritional risk
profiles. Sensitivity analyses explored alternative cutoff
criteria based on the MAPT population distribution. Those
included serum D (15 ng/mL vs. 20) and total plasma
HCy (18.1 mmol/L vs. 14), whereas n-3 PUFA
remained at the 25th percentile (Supplementary Fig. 1
and Supplementary Table 1).2.6. Analytical approach and hypothesis testing2.6.1. Descriptive statistics
Demographic and clinical characteristics and their distri-
butions were calculated for each nutrient biomarker. Histo-
grams illustrate the frequency and spread of each nutrient
biomarker.
2.6.2. Statistical analysis
Cognitive composite Z score trajectories during 3 years as
a function of baseline NRI scores were fit using linear
mixed-effects models. The initial construction of the NRI
scores assumed that the estimated magnitude of effect of
each nutritional risk factor on cognition was homogeneous.
Therefore, an NRI-1 is achieved by suboptimum concentra-
tion of any one of the three biomarkers. NRI-2 did not
discriminate on which two nutrient biomarkers met the sub-
optimum criteria. Then the same models were constructed
assuming that each nutritional risk factor estimated that
magnitude of effect on cognition was heterogenous. This
approach discretely defined nutritional risk by labeling the
NRI-1 and NRI-2 scores depending on the specific nutrients
or combinations meeting the suboptimum concentration
criteria (i.e., NRI-1 [O3]; NRI-1 [D]; and NRI-1 [HCy];
NRI-2 [O3-HCy]; NRI-2 [O3-D]; and NRI-2 [HCy-D]). Co-
variates in the mixed-effects models included time measured
as years from baseline, the age of participants in years,
gender, education in years, trial arm allocation (placebo,MDI, MDI plus n-3 PUFA supplementation, and n-3
PUFA supplementation), and trial arm ! time interaction
with intercept and slope as random effects (model 1).
Nonlinear effects including time squared and time quadratic
effects were examined in preliminary analyses but failed to
improve the goodness of fit of the model. Therefore, linear
mixed-effects models are reported. We further adjusted
for apolipoprotein E (APOE) ε4 (carrier vs. not) and
baseline clinical dementia rating (CDR) (CDR 5 0 vs.
CDR 5 0.5). After completing the primary analysis, two
sensitivity analyses were conducted: (1) redefining the sub-
optimum cutoffs for nutrient biomarkers using the MAPT
population percentiles (e.g., lowest 25th percentile for n-3
PUFA and 25-hydroxyvitamin D and highest 25th percentile
for HCy) and (2) restriction of the analysis to the MAPT par-
ticipants naive to the n-3 PUFA supplementation (i.e., the
placebo and MDI arms only).3. Results
Nutrient biomarker analysis included 43% of the total
MAPT participants (n5 729 of 1679) and yielded an analyt-
ical cohort of 712 representing approximately 25% of the to-
tal population within each trial arm (Table 1). The mean
concentrations for n-3 PUFA, D, and HCy were 5.8 wt%,
23.7 ng/mL, and 15.8 mmol/L, respectively (Table 1). The
distribution of their concentrations (i.e., 0, 25th, median,
75th, and 100th percentiles) was 2.3, 4.8, 5.7, 6.7, 11.8 wt
% (n-3 PUFA); 3, 15, 22, 31, and 123 ng/mL (D); and 5.6,
12.2, 14.9, 18.1, and 49.3 mmol/L (HCy) (Supplementary
Fig. 1 and Supplementary Table 1).
Nutritional risk was identified in 80.4% of the population
(NRI 1 5 573 of 712), and 40.8% had multiple nutritional
risk factors (NRI 2 5 291 of 712). Prevalence of subopti-
mum n-3 PUFA, D, and HCy was 26.4%, 45.2%, and
58.9%, respectively. Therewere 19.5% (n5 139) participants
without nutritional risk (i.e., NRI-0), 39.6% (n 5 282) with
one nutritional risk factor (i.e., NRI-1), 31.6% (n 5 225)
with two nutritional risk factors (NRI-2), and 9.3% (n 5 66)
with maximum nutritional risk (i.e., NRI-3) (Table 2).3.1. NRI and 3-year age-related cognitive trajectories in
older adults
In adjusted mixed-effects models, participants without
nutritional risk (NRI-0) had superior baseline cognitive per-
formance (Fig. 1A; Table 3). The annual rate of decline on
the cognitive composite Z score across all participants was
20.008 standard units (SU)/y. Fig. 1 illustrates the cognitive
enhancement observed during 3 years in older adults without
nutritional risk (NRI-0: b5 0.0168 SU/y; b5 0.05 SU after 3
years). Each additional nutritional risk factor detected and
identified at baseline corresponded with an incremental wors-
ening in the cognitive trajectory (e.g., NRI-1: b 5 20.0451
SU/y; NRI-2: b5 20.0875 SU/y; and NRI-3: b520.1101
SU/y) (Fig. 1A; Table 3). The estimated difference in rates
Table 1
Baseline characteristics of the MAPT analytical cohort (n 5 712)
Total
Omega-3 PUFA Serum 25-OH-D Plasma homocysteine
Optimum
(n 5 524)
Suboptimum
4.82 wt%
(n 5 188)
Optimum
(n 5 390)
Suboptimum
20 ng/mL
(n 5 322)
Optimum
(n 5 292)
Suboptimum
14 mmol/L
(n 5 420)
Age, y; mean (SD)* 75.6 (4.5) 75.5 (4.5) 76.1 (4.5) 75.0 (4.2) 76.3 (4.8) 74.6 (4.0) 76.3 (4.7)
Women, n (%) 480 (67.4) 356 (67.9) 124 (66.0) 266 (68.2) 214 (66.5) 231 (79.1) 249 (59.3)
Education
No diploma/primary school 168 (23.6) 104 (19.9) 64 (34.0) 71 (18.2) 97 (30.1) 66 (22.6) 102 (24.3)
Secondary education 244 (34.3) 184 (35.1) 60 (31.9) 148 (37.9) 96 (29.8) 98 (33.5) 146 (34.8)
High-school diploma 104 (14.6) 82 (15.7) 22 (11.7) 52 (13.3) 52 (16.1) 48 (16.4) 56 (13.3)
University level 196 (27.5) 154 (29.4) 42 (22.3) 119 (30.5) 77 (23.9) 80 (27.4) 116 (27.6)
MMSE 28.0 (1.6) 28.1 (1.6) 27.8 (1.8) 28.1 (1.6) 27.9 (1.7) 27.9 (1.6) 28.1 (1.6)
Cognitive Z score 20.029 (0.70) 0.015 (0.66) 20.15 (0.78) 0.049 (0.66) 20.12 (0.73) 0.07 (0.63) 20.10 (0.74)
APOE ε4 available, n (%) 624 (87.6) 472 (90.1) 152 (80.9) 346 (88.7) 278 (86.3) 261 (89.4) 363 (86.4)
APOE ε4 carrier, n (%) 129 (20.7) 97 (20.6) 32 (21.1) 74 (21.4) 55 (19.8) 50 (19.2) 79 (21.8)
Treatment arm
O3 180 (25.3) 126 (24.1) 54 (28.9) 96 (24.6) 84 (26.1) 67 (22.9) 113 (26.9)
MDI 176 (24.7) 141 (26.9) 34 (18.2) 94 (24.1) 82 (25.5) 77 (26.4) 99 (23.6)
O3 1 MDI 177 (24.9) 126 (24.1) 51 (27.3) 100 (25.6) 77 (23.9) 71 (24.3) 106 (25.2)
Placebo 179 (25.1) 131 (25.0) 48 (25.7) 100 (25.6) 79 (24.5) 77 (26.4) 102 (24.3)
Omega-3 PUFA, wt% 5.8 (1.5) 6.4 (1.2) 4.0 (0.6) 5.9 (1.5) 5.6 (1.4) 6.2 (1.5) 5.5 (1.4)
Serum 25-OH-D, ng/mL 23.7 (12.3) 24.1 (12.5) 22.6 (11.7) 31.7 (10.4) 13.7 (4.3) 24.0 (12.9) 23.5 (11.8)
Plasma homocysteine, mmol/L 15.8 (5.3) 15.3 (5.3) 17.1 (5.3) 15.6 (5.0) 16.0 (5.7) 11.4 (1.7) 18.8 (4.9)
Abbreviations: MAPT, multidomain Alzheimer prevention trial; PUFA, polyunsaturated fatty acid; Serum 25-OH-D, serum 25-hydroxy vitamin D; SD, stan-
dard deviation; MMSE, Mini-Mental State Examination; APOE, apolipoprotein E; O3, omega-3 PUFA intervention; MDI, multidomain intervention.
*Mean (SD) or number (% of total).
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on the order of magnitude expected with approximately
4 years of aging (20.11 [NRI-3]/20.03 [age]5 3.6).
Because of the potential heterogeneity in the effect size of
each nutritional risk factor, we explored each distinct six
additional NRI profiles (e.g., NRI-1 due to subotimum n-3
PUFA (NRI-1 [O3]), NRI-1 [D], NRI-1 [HCy], and NRI-2
due to suboptimum n-3 PUFA and vitamin D[O3 1 D],
NRI-2 [O3 1 HCy], NRI-2 [D 1 HCy]) (Table 2). NRI-1Table 2
The Prevalence and Nature of Nutritional Risk in Older Adults using Nutrient Bi
NRI
RBC n-3 PUFA Serum 25-O
Optimum Suboptimum Optimum
0
NRI-0
1
NRI-1 (HCy)
NRI-1 (D)
NRI-1 (O3)
2
NRI-2 (HCy 1 D)
NRI-2 (O3 1 D)
NRI-2 (O3 1 HCy)
3
NRI-3 (O3 1 D 1 HCy)
Total prevalence 26.4% (188/712)
Abbreviations: MAPT, multidomain Alzheimer prevention trial; NRI, nutritiona
hydroxyvitamin D; HCy, homocysteine; D, vitamin D; O3, omega-3 PUFA interv
*Suboptimum status requires one of the following: omega-3 PUFA (O3)4.82 w[D] was the only nutritional risk factor that independently
associated with cognitive decline (b 5 20.06 SU/y)
(Fig. 1B; Table 4). However, any two nutritional risk factors
combined was associated with acceleration in rates of cogni-
tive decline ranging from20.07 SU/y (NRI-2 [O31 HCy])
to 20.09 SU/y (NRI-2 p[HCy 1 D]) (Fig. 1C; Table 4).
Further adjustment for baseline CDR (0 vs. 0.5), APOE ε4
carrier versus not and their interaction with time produced
nomaterial changes to the estimated effects (data not shown).omarkers in the MAPT (n 5 712)*
H D Plasma homocysteine Sample size
Suboptimum Optimum Suboptimum n (%)
139 (19.5)
156 (21.9)
104 (14.6)
22 (3.1)
125 (17.6)
27 (3.8)
73 (10.3)
66 (9.3)
45.2% (322/712) 58.9% (420/712)
l risk index; PUFA, polyunsaturated fatty acid; Serum 25-OH D, serum 25-
ention.
t%, total serum 25-OH-D (D)20 ng/mL, or plasma total HCy14 mmol/L.
Fig. 1. Mean 3-year cognitive trajectories by baseline NRI in the multidomain Alzheimer prevention trial (n 5 712). NRI increases by one point for the
following: omega-3 polyunsaturated fatty acid(EPA1DHA) 4.82 wt%; serum 25-hydroxyvitamin D 20 ng/mL; plasma homocysteine 14 mmol/L. (A)
Mean 3-year cognitive composite Z score trajectories by baseline NRI 0, 1, 2, and 3. (B) Mean 3-year cognitive composite Z score trajectories by each distinct
NRI-1 profilewith NRI-0 and NRI-3 included for comparison. (C)Mean 3-year cognitive composite Z score trajectories by each distinct NRI-2 profilewith NRI-
0 and NRI-3 included for comparison. Abbreviations: NRI, nutritional risk index; SU, standard units; HCy, homocysteine.
G.L. Bowman et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 953-963958The sensitivity analysis that redefined thenutrient biomarker
cutoffs using MAPT population quartiles (Supplementary
Table 1) produced consistent results (e.g., NRI-1 5 20.04
SU/y, P 5 .0213; NRI-2 5 20.06 SU/y, P 5 .006; and NRI-
3 5 20.17 SU/y, P 5 .009) (Supplementary Table 2). Thesensitivity analysis restricted to MAPT participants naive to
n-3 PUFA supplementation also produced consistent results
(placebo and MDI arms, n 5 355: NRI-1 5 20.08 SU/y,
P 5 .006; NRI-2 5 20.09 SU/y, P 5 .002; and NRI-
3520.19 SU/y, P5 .0004) (Supplementary Table 3).
Table 3
Mean differences in cognitive trajectories according to the NRI scores in the
MAPT (n 5 712)
characteristic
ß coefficient
estimate SE Pr . |t|
Intercept 2.4787 0.4296 ,0.0001
Age, y 20.0329 0.0055 ,0.0001
Time, y 0.0168 0.0211 0.4256
Gender, men compared
with women
20.1869 0.0532 0.0005
Education
No diploma/primary school 0 — —
Secondary education 0.1004 0.0665 0.1317
High-school diploma 0.4657 0.0828 ,0.0001
College or more 0.4671 0.0706 ,0.0001
NRI, baseline
0 (reference group) 0 — —
1 20.1408 0.0686 0.0403
2 20.1010 0.0722 0.1621
3 20.3864 0.1004 0.0001
NRI! time (y)
0 (reference group) 0 — —
1 20.0451 0.0211 0.0331
2 20.0875 0.0219 ,0.0001
3 20.1101 0.0327 0.0008
NOTE. Model adjusted for baseline age, gender, education, trial arm, and
trial arm ! time interaction; primary outcome measure is the cognitive
composite Z score. NRI increases by one point for each of the following:
omega-3 PUFA (O3)4.82 wt%; serum 25-OH D 20 ng/mL; and plasma
homocysteine 14 mmol/L.
Abbreviations: NRI, nutritional risk index; MAPT, multidomain Alz-
heimer prevention trial; SE, standard error.
Table 4
Mean differences in cognitive trajectories according to the baseline NRI in
the MAPT (n 5 712)
characteristic
Omega-
3 PUFA
Serum
25-
OH-D
Plasma
HCy
ß
coefficient
estimate SE P
NRI, baseline
0 0 0 0 0 — —
1 (HCy) 0 0 1 20.1168 0.0775 .1320
1 (D) 0 1 0 20.1880 0.0863 .0296
1 (O3) 1 0 0 20.0917 0.1544 .5526
2 (HCy 1 D) 0 1 1 20.1114 0.0828 .1785
2 (O3 1 HCy) 1 0 1 20.0809 0.0949 .3943
2 (O3 1 D) 1 1 0 20.1025 0.1412 .4680
3 (O3 1 D 1 HCy) 1 1 1 20.3859 0.1006 .0001
NRI! time (y)
0 0 0 0 0 — —
1 (HCy) 0 0 1 20.0383 0.0240 .1121
1 (D) 0 1 0 20.0603 0.0267 .0243
1 (O3) 1 0 0 20.0142 0.0538 .7924
2 (D 1 HCy) 0 1 1 20.0969 0.0253 .0001
2 (O3 1 HCy) 1 0 1 20.0712 0.0300 .0179
2 (O3 1 D) 1 1 0 20.0872 0.0449 .0525
3 (O3 1 D 1 HCy) 1 1 1 20.1098 0.0328 .0008
NOTE.Model adjusted for baseline age, gender, education, trial arm, trial
arm! time interaction; primary outcome is MAPT cognitive composite Z
score. NRI increases by one point for each of the following: omega-3 PUFA
(O3) 4.82 wt%; serum 25-OH-D (D) 20 ng/mL; and plasma
HCy 14 mmol/L.
Abbreviations: NRI, nutritional risk index; MAPT, multidomain Alzhem-
ier prevention trial; PUFA, polyunsaturated fatty acid; Serum 25-OH-D,
serum 25-hydroxyvitamin D; HCy, homocysteine; SE, standard error; D,
vitamin D; O3, omega-3 PUFA intervention.
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Nutritional risk for cognitive decline was identified in
more than 80% of the population, and 40% had multiple
nutritional risk factors. Participants without nutritional risk
exhibited learning effects on repeat cognitive testing,
whereas each additional nutritional risk factor corresponded
with a stepwise incremental acceleration in rates of cognitive
decline. These estimated effects were unattributable to age,
gender, education, trial treatment allocation, baseline cogni-
tive status, or APOE ε4 genotype. A blood-based NRI may
facilitate more individualized and conclusive nutritional
strategies for prevention of cognitive decline in the future.
The observations in the study are biologically plausible.
Both in vitro and in vivo studies have demonstrated that
the n-3 PUFA and DHA can promote neurogenesis [50], in-
crease synaptic activity [51,52], reduce Ab production and
accumulation [53], and preserve memory and learning
[54,55]. The n-3 PUFA precursor to DHA, EPA, has
anti-inflammatory properties such as the downregulation of
soluble intercellular adhesion molecule-1 that modulates
the migration of neutrophils into the CNS across the
blood-brain barrier [20,56,57]. Total n-3 PUFA in peripheral
circulation is associated with cerebral cortical tissue
concentrations in older adults at autopsy supporting the
notion that the brain meets its nutritional demands via
peripheral circulation measured in our study [58].Hyperhomocysteinemia as one indicator of disturbed
one-carbon metabolism can induce the overexpression of
tau kinases (e.g., Cdk5 kinase), rarefaction of the cerebral
capillaries, and impairment of nitric oxide and endothelial
cell-mediated vasodilation [21,59,60]. Hyperhomocysteine-
mia may indirectly obstruct the methylation of
phosphatidylethanolamine to phosphatidylcholine by phos-
phatidylethanolamine N-methyltransferase (PEMT) [61].
The PEMT pathway may be essential to the liberation of
hepatic DHA into circulation for delivery to the brain in
support of synaptic structure and function [62,63]. The
PEMT pathway may explain our observation that n-3
PUFA and HCy were not independently associated with
cognitive decline but when combined acceleration in cogni-
tive decline ensued [64]. On the other hand, suboptimum D
was associated with cognitive decline in the setting with n-3
PUFA and HCy optimum. This may be explained by
experiments showing that depleted D induces cortical amy-
loid deposition indirectly by downregulating the low-density
lipoprotein receptor-related protein-1 involved in clearance
of soluble CNS Ab oligomers [23–28,65]. Another contrib-
uting factor may have been the prevalence of D deficiency in
the population (.45%) and therefore more power to observe
the association. Together, these results suggest that older
adults with n-3 PUFA .4.82 wt%, D . 20 ng/mL, and
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years. These may represent actionable targets for experi-
mental modulation and further empirical research in larger
more diverse populations.
The concept of an NRI for cognition is attractive because it
offers a reliable, objective, and quantitative measure of the
nutrition-related risk for cognitive decline. The nutrient
biomarker selection was based on their broad and potentially
interactive biological activity together with their sensitivity
to diet and supplementation. The cutoffs were defined a priori
using an admittedly fragmented evidence base where distinct
nutritional requirements for cognitive health do not currently
exist. Therefore, it was necessary and important to explore
opposing cutoffs in this initial hypothesis-driven study. n-3
PUFAwas maintained at the lowest quartile in the study pop-
ulation (4.82 wt%) because the evidence base for optimum/
suboptimum is in its infancy. However, both serumD (15 vs.
20 ng/mL) and HCy (18.1 vs. 14 mmol/L) were set at
more extreme suboptimum cutoffs defined by theMAPT pop-
ulation distribution. The estimated effects of theNRIon cogni-
tive decline was essentially unchanged with perhaps one
exception; NRI-3 was higher in magnitude (20.11 SU/y to
20.17 SU/y). This increase in estimated effect size was
encouraging and offers one indicationof a potential dose effect
of more nutritional risk corresponding tomore rapid cognitive
decline (Supplementary Table 3 vs. Table 3).
TheMAPTwas deemed null by the investigators [30]. We
leveraged this as an opportunity to explore the NRI concept
with trial arm allocation adjustment statistically as a covari-
ate in our models. Adding further assurance, analysis was
restricted to participants naive to n-3 PUFA supplementation,
and the results were consistent with the possible exception of
greater effects ofNRI on rates of cognitive decline (e.g., NRI-
1: b520.08 vs.20.04 SU/y; NRI-3: b520.19 vs.20.11
SU/y). In an exploratory analysis using a three-way interac-
tion term in the model (trial arm! NRI! time), we deter-
mined that the MAPT interventions remained null regardless
of baseline NRI (data not shown). The limited sample size
and the fact that a multinutrient combination (n-3 PUFA,
D, and HCy-lowering B vitamins) was not included in
MAPT may explain these findings and prevent any firm con-
clusions at this point. The consistent results regardless of the
approach to these data are remarkable and encourage support
for the robustness of the primary findings.
Thenutrient biomarker concentrations are comparablewith
those seen in other studies with some exceptions. The mean
plasma HCy in the MAPT population was 15.8 mmol/L. This
is somewhat higher than what has been observed in older US
adults (70 years and older) in both the prefolate and postfolate
fortification eras (~11–14mmol/L) [66,67]. There are several
possible explanations, including differences in the B vitamin
nutriture, renal status of the populations, and duration of
time before the blood spin down.However, it is perhaps impor-
tant to note that hyperhomocysteinemia in isolation was not
associated with cognitive decline unless it was accompanied
by suboptimum D, n-3 PUFA, or both. Another point ofconsideration is that all nutritional risk groups (NRI 1)
were comparedwith a reference group considered as optimum
nutritional status in the setting of cognitive performance (NRI-
0). There are other nutritional interventions showing greater
effects of HCy-lowering B vitamins on slowing cognitive
decline in older adultswith hyperhomocysteinemia and higher
n-3 PUFA at baseline [9]. Otherwise, the distributions
observed for D [65,68] and n-3 PUFA [69,70] were similar
to older European and US adults.
Despite the substantial evidence in support of large ran-
domized controlled trials of high-dose nutrient supplementa-
tion, most have produced disappointing results calling into
question whether nutrition can indeed reduce the risk of
cognitive decline and dementia, including Alzheimer’s dis-
ease. Many of these well-executed interventions may have
underappreciated nutritional status and nutrient interaction
in their design and interpretations. Many participants in
most single or few nutrient supplement trials for prevention
of cognitive decline have included significant proportions of
people already replete in the nutrient understudy
[2,3,6,8,71]. Perhaps the NRI concept will facilitate more
definitive nutritional interventions in the future through a
more individualized approach in identifying people in the
general population at nutritional risk for cognitive decline.
Operational challenges exist, and the deployment of a
blood-based NRI is not trivial requiring unique expertise
and resources. The next generation of nutritional interven-
tions should inform on the utility and effectiveness of incor-
porating the NRI concept for subject enrichment (i.e., those
at nutritional risk), monitoring adherence and describing
dose responses (clinicaltrials.gov: NCT01953705 and
NCT03080675).
In conclusion, optimizing n-3 PUFA, D, and HCy to pro-
mote cognitive health is a biologically plausible and testable
hypothesis that warrants experimental and further observa-
tional study. Expanding the application of nutrient biomarkers
may enable the establishment of distinct nutritional require-
ments for healthy brain aging that currently do not exist.Acknowledgments
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1. Systematic review: The omega-3 PUFAs (n-3
PUFA), vitamin D, and homocysteine are each
independently associated with cognitive decline, yet
clinical trials of high-dose dietary supplements have
been mostly disappointing raising questions as to
whether nutrition indeed has a role in prevention of
age-related cognitive decline and dementia. How-
ever, most of these studies have focused on supple-
mentation in the general population in which many
participants are already replete in the nutrient un-
derstudy. We tested the hypothesis that an NRI
including biomarkers of diet quality (erythrocyte n-3
PUFA, serum 25-hydroxyvitamin D, and plasma
homocysteine) explains the 3-year cognitive trajec-
tories in older adults at risk for dementia in the
multidomain Alzheimer prevention trial.
2. Interpretation: Participants with optimum nutritional
status (NRI-0) exhibited cognitive enhancement dur-
ing the 3 years of follow up. However, each addi-
tional NRI point increase was associated with a
stepwise incremental acceleration in rates of cogni-
tive decline.
3. Future directions: A blood-based NRI may help
identify subsets of the general population well suited
for the evidence-based nutritional strategies that
promote cognitive health. The simultaneous optimi-
zation of these biomarkers of diet quality may pre-
vent age-related cognitive decline. The broader
utilization of biomarkers in nutrition studies may
help raise attention to the nutritional requirements
for optimum brain health with aging.
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